VB-201

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529806

CAS#: 630112-41-3

Description: VB-201, also called CI-201, is a Toll-like receptor-2 (TLR-2) antagonist potentially for the treatment of atherosclerosis.


Price and Availability

Size
Price

Size
Price

Size
Price

VB-201 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529806
Name: VB-201
CAS#: 630112-41-3
Chemical Formula: C29H60NO8P
Exact Mass: 581.41
Molecular Weight: 581.77
Elemental Analysis: C, 59.87; H, 10.40; N, 2.41; O, 22.00; P, 5.32


Synonym: CI-201, VB-201, CI 201; VB 201, CI201; VB201

IUPAC/Chemical Name: (R)-2-(4-carboxybutoxy)-3-(hexadecyloxy)propyl (2-(trimethylammonio)ethyl) phosphate

InChi Key: JGGNOCUEWOGWPL-MUUNZHRXSA-N

InChi Code: InChI=1S/C29H60NO8P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-19-23-35-26-28(36-24-20-18-21-29(31)32)27-38-39(33,34)37-25-22-30(2,3)4/h28H,5-27H2,1-4H3,(H-,31,32,33,34)/t28-/m1/s1

SMILES Code: O=P(OC[C@H](OCCCCC(O)=O)COCCCCCCCCCCCCCCCC)([O-])OCC[N+](C)(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Mendel I, Feige E, Yacov N, Salem Y, Levi I, Propheta-Meiran O, Shoham A, Ishai E, George J, Harats D, Breitbart E. VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37. doi: 10.1111/cei.12212. PubMed PMID: 24116867; PubMed Central PMCID: PMC3898561.

2: Feige E, Yacov N, Salem Y, Levi I, Mendel I, Propheta-Meiran O, Shoham A, Hait-Darshan R, Polonsky O, George J, Harats D, Breitbart E. Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE⁻/⁻ mice. Atherosclerosis. 2013 Aug;229(2):430-9. doi: 10.1016/j.atherosclerosis.2013.06.005. PubMed PMID: 23880199.

3: Mendel I, Shoham A, Propheta-Meiran O, Ishai E, Halperin G, Feige E, Breitbart E. A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. J Neuroimmunol. 2010 Sep 14;226(1-2):126-35. doi: 10.1016/j.jneuroim.2010.06.011. PubMed PMID: 20663571.

4: Mendel I, Yacov N, Shoham A, Ishai E, Breitbart E. Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. Dig Dis Sci. 2016 Sep;61(9):2545-53. doi: 10.1007/s10620-016-4159-5. PubMed PMID: 27074921; PubMed Central PMCID: PMC4980417.

5: Feige E, Mendel I, George J, Yacov N, Harats D. Modified phospholipids as anti-inflammatory compounds. Curr Opin Lipidol. 2010 Dec;21(6):525-9. doi: 10.1097/MOL.0b013e32833f2fcb. Review. PubMed PMID: 20827191.